Introduction
============

Subclinical hypothyroidism (SCH) is defined as a mildly elevated serum thyroid-stimulating hormone (TSH) level with a serum free thyroxine (FT4) level within the normal range ([@bib1]). While treatment of SCH is not mandatory in most cases, thyroid hormone replacement can be considered in pregnant patients who have TSH persistently \>10 µIU/mL, associated symptoms or are at high risk of overt hypothyroidism ([@bib2], [@bib3]). SCH is frequently detected in the population with a prevalence of 3--12% ([@bib4], [@bib5]). The prevalence is dependent on the TSH reference range used, and the TSH level is known to be strongly influenced by sex, area of residence, iodine intake and the presence of autoantibodies ([@bib4], [@bib6], [@bib7]). In iodine-rich areas, a prevalence of SCH of up to 18% has been reported ([@bib2], [@bib7], [@bib8]). Thyroid diseases including SCH are known to be more prevalent in women than in men ([@bib9], [@bib10]). Approximately 5--15% of women are positive for thyroid autoantibodies, either anti-thyroid peroxidase antibody (TPOAb) or anti-thyroglobulin antibody ([@bib11], [@bib12]). The higher incidence of thyroid autoantibodies in women is reported to account for their higher incidence of thyroid disease ([@bib9], [@bib13]). However, other sex-specific risk factors for SCH development have not been elucidated. In addition, the TSH reference range required to define the SCH varies depending on the target population, and the normal reference range varies between subgroups in the same population. For example, in a study of the Korean population, the prevalence of SCH varied from 0.16% to 17.63%, depending on the particular population being studied ([@bib2], [@bib14], [@bib15]). In the present study, we investigated the prevalence of SCH in Korean adults based on data from the most recent nationally representative epidemiological survey, the Sixth Korea National Health and Nutrition Examination Survey (KNHANES VI) and examined the risk factors for the occurrence of SCH according to sex.

Methods
=======

Study population
----------------

KNHANES VI was carried out by the Korea Centers for Disease Control and Prevention (CDC) and comprises a health interview survey, a health examination survey and a nutrition survey, using a stratified multistage probability sampling design. Informed written consent for participation was obtained from all study subjects. In addition, the study was approved by the Korea CDC Institutional Review Board. TSH reference range was calculated by two methods, and the subjects were divided into two groups according to the method used. First, we used the TSH reference range (0.35--5.5 µIU/mL) provided by the manufacturers of the test kit (Roche Diagnostics) to define SCH (SCH-M). Of the 22,948 Korean participants, 4914 aged \<19 years were excluded. Subjects who were pregnant (*n* = 10), had delivered a child within the previous year (*n* = 62), had a history of treatment for thyroid disease (*n* = 58), for whom insufficient urine iodine data were available (*n* = 372), for whom insufficient FT4 data were available or were not within the normal range (*n* = 12,159) and for whom insufficient TSH data were available or were \<0.35 µIU/mL (*n* = 69) were excluded from the analysis. Ultimately, 4888 participants were included in this study. Second, SCH was defined using a TSH reference range based on the enrolled population (0.62--6.68 µIU/mL) (SCH-P). Of the initial 22,948 Korean participants, 4801 subjects were selected for this analysis by excluding those who did not meet the inclusion criteria (subjects aged \<19 years (*n* = 4914), pregnant (*n* = 10), history of delivery within 1 year (*n* = 59), history of treatment for thyroid disease (*n* = 57), insufficient urine iodine data (*n* = 368), insufficient FT4 data or not within the normal range (*n* = 12,643) and insufficient TSH data or value \<0.62 µIU/mL (*n* = 167).

Measurements
------------

All measurements and questionnaires were collected by specially trained investigators. Detailed anthropometric measurements were carried out as in previous studies ([@bib16], [@bib17], [@bib18]). Height and body weight were measured as part of the health examination. Body mass index (BMI) was calculated from the measured height and weight. BMI was categorized as underweight (\<18.5 kg/m^2^), normal weight (≥18.5 kg/m^2^, \<23 kg/m^2^), overweight (≥23 kg/m^2^, \<25 kg/m^2^) or obese (≥25 kg/m^2^). Waist circumference was measured to the nearest 0.1 cm at the narrowest point between the lowest rib and the uppermost lateral border of the right iliac crest. Blood pressure was also measured by trained technicians using a Baumanometer mercury sphygmomanometer (WA Baum, Copiague, NY, USA), and all the subjects were seated for at least 5 min before the measurements were taken. Creatinine, TSH, FT4 and TPOAb were measured from sampled blood collected after overnight fasting. TSH was measured using an E-TSH kit (Roche Diagnostics), for which the reference range was 0.35--5.50 µIU/mL. FT4 was measured using an E-Free T4 kit (Roche Diagnostics) for which the reference range was 0.89--1.76 ng/mL. TPOAb was measured using an E-Anti-TPO kit (Roche Diagnostics); the normal range for TPOAb in humans is \<34.0 IU/mL. Serum creatinine was measured using a Hitachi Automatic Analyzer 7600-210 (Hitachi) and iodine intake status was evaluated using the urine iodine creatinine ratio (UICR) determined using inductively coupled plasma--mass spectroscopy (PerkinElmer). Socio-economic status was defined according to income categorized into quartiles. Chronic kidney disease (CKD) was divided into five stages based on the glomerular filtration rate by referring to the Kidney Disease Outcomes Quality Initiative classification ([@bib19]).

Definition of SCH
-----------------

SCH was defined as normal serum FT4 levels with serum TSH levels above the reference range. However, SCH-M (0.35--5.5 µIU/mL) differed from that defined using the 2.5--97.5 percentiles of serum TSH levels in the studied population (SCH-P, 0.62--6.68 µIU/mL). Although clinical practice guidelines suggest the use of population-based reference ranges for TSH ([@bib20]), the upper limit of TSH (6.68 µIU/mL) acquired from the population data was higher than the cut-off values for SCH usually used in clinical practice. However, the clinical value of TSH upper limit values requires verification. Thus, we analyzed the data using both SCH-M and SCH-P.

Statistical analysis
--------------------

Statistical analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC, USA). *P* values \<0.05 were considered significant. Data are expressed as numbers and percentages or as means ± [s.d.]{.smallcaps} Differences between subjects with SCH and without SCH were evaluated using the Wilcoxon rank-sum test or the *χ* ^2^ test, as appropriate. Differences between the four quartiles of serum TSH level were determined using a generalized linear model (Duncan's test of multiple comparisons). Multivariable adjusted logistic regression analysis was conducted to determine odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of SCH across variables. Because of the complex sampling design, a sampling weight method was used to assign participants representative of the Korean population for the analysis of data. Detailed characteristics of the statistical analysis of KNHANES have been reported previously ([@bib16], [@bib21]).

Results
=======

Baseline characteristics of the subjects
----------------------------------------

### Using the manufacturer's suggested TSH reference range (SCH-M)

The baseline characteristics of 4888 participants were analyzed, as were age, sex, BMI, region of residence, family history of thyroid disease, smoking status, UICR quartile, the presence of TPOAb and CKD staging ([Table 1](#tbl1){ref-type="table"}). The subjects were distributed evenly in age between 19 and 69 years, and only 94 subjects were aged over 70 years. There were 2343 (46.1%) women, most of whom were urban area residents (74.4%). Overall, 4644 (95.0%) subjects had no family history of thyroid disease and 2679 (54.3%) were non-smokers. UICR was uniformly distributed by quartile, and TPOAb was undetectable in 4556 (93.5%) subjects. Most participants (96%) were found to be in CKD stages 1 and 2. The results of analysis of baseline characteristics by sex are summarized in [Table 2](#tbl2){ref-type="table"}. There was a clear difference between men and women for smoking status: of the 2545 men, 1933 (76.0%) were smokers, while only 276 of 2343 (11.8%) women were smokers. Table 1Baseline characteristics of subjects when kit manufacturer suggested TSH reference range (0.35--5.5 µIU/mL) is used.Total subjects (n = 4888)Subclinical hypothyroidismP valueNo (n = 4597)Yes (n = 291)Age (years)0.064 19--29998 (20.4%)944 (20.5%)54 (18.6%) 30--39897 (18.4%)855 (18.6%)42 (14.4%) 40--49956 (19.6%)903 (19.6%)53 (18.2%) 50--591016 (20.7%)935 (20.4%)81 (27.8%) 60--69927 (19.0%)877 (19.1%)50 (17.2%) 70 and above94 (1.9%)83 (1.8%)11 (3.8%)Sex\<0.001 Male2545 (53.9%)2434 (54.8%)111 (39.7%) Female2343 (46.1%)2163 (45.2%)180 (60.3%)BMI (kg/m2)0.436 \<18.5210 (4.0%)197 (4.1%)13 (4.5%) ≥18.5, \<231891 (38.1%)1788 (38.4%)103 (35.4%) ≥23, \<251168 (24.4%)1096 (24.3%)72 (24.7%) ≥251619 (33.5%)1516 (33.2%)103 (35.4%)Region of residencea0.307 Rural1312 (25.6%)1239 (25.8%)73 (22.8%) Urban3576 (74.4%)3358 (74.2%)218 (77.2%)Family history of thyroid disease0.787 No4644 (95.0%)4366 (95.0%)278 (95.4%) Yes244 (5.0%)231 (5.0%)13 (4.6%)Smoking\<0.001 No2679 (54.3%)2477 (53.4%)202 (70.4%) Yes2209 (46.7%)2120 (46.6%)89 (29.6%)UICRb\<0.001 Quartile 11246 (25.1%)1207 (25.8%)39 (13.0%) Quartile 21216 (25.0%)1159 (25.3%)57 (21.1%) Quartile 31198 (24.8%)1122 (24.7%)76 (26.6%) Quartile 41228 (25.1%)1109 (24.2%)119 (39.3%)Anti-TPO Ab\<0.001 Absence4556 (93.5%)4325 (94.4%)231 (78.0%) Presence332 (6.5%)272 (5.6%)60 (22.0%)CKD stage0.494 Stage 1, 24707 (96.0%)4428 (96.0%)279 (96.8%) Stage 3, 4, 5181 (4.0%)169 (4.0%)12 (3.2%)[^1] Table 2Association with subclinical hypothyroidism according to gender when kit manufacturer suggested TSH reference range is used.Male total (n = 2545)Subclinical hypothyroidism (male)P valueFemale total (n = 2343)Subclinical hypothyroidism (female)P valueNo (n = 2434)Yes (n = 111)No (n = 2163)Yes (n = 180)Age (years)0.6960.017 19--29530 (20.8%)504 (20.7%)26 (23.4%)468 (20.0%)440 (20.3%)28 (15.6%) 30--39491 (19.3%)472 (19.4%)19 (17.1%)406 (17.3%)383 (17.7%)23 (12.8%) 40--49502 (19.7%)481 (19.8%)21 (18.9%)454 (19.4%)422 (19.5%)32 (17.8%) 50--59502 (19.7%)481 (19.8%)21 (18.9%)514 (21.9%)454 (21.0%)60 (33.3%) 60--69470 (18.5%)451 (18.5%)19 (17.2%)457 (19.5%)426 (19.7%)31 (17.2%) 70 and above50 (2.0%)45 (1.8%)5 (4.5%)44 (1.9%)38 (1.8%)6 (3.3%)BMI (kg/m2)0.1680.393 \<18.565 (2.6%)64 (2.5%)1 (0.9%)145 (6.2%)133 (6.0%)12 (4.8%) ≥18.5, \<23837 (32.9%)808 (33.7%)29 (26.2%)1054 (50.0%)980 (44.0%)74 (38.9%) ≥23, \<25659 (25.9%)631 (26.2%)28 (25.2%)509 (21.7%)465 (22.1%)44 (27.6%) ≥25984 (38.7%)931 (37.6%)53 (47.7%)635 (27.1%)585 (27.9%)50 (28.7%)Region of residencea0.1610.009 Rural693 (27.2%)658 (25.6%)35 (32.4%)619 (26.4%)581 (26.1%)38 (16.5%) Urban1852 (72.8%)1776 (74.4%076 (67.6%)1724 (73.6%)1582 (73.9%)142 (83.5%)Family history of thyroid disease0.9810.596 No2442 (96.0%)2334 (95.7%)108 (95.8%)2202 (94.0%)2032 (94.1%)170 (95.2%) Yes103 (4.0%)100 (4.3%)3 (4.2%)141 (6.0%)131 (5.9%)10 (4.8%)Smoking0.0200.093 No612 (20.1%)577 (24.2%)35 (35.8%)2067 (88.2%)1900 (88.7%)167 (93.1%) Yes1933 (79.9%)1857 (75.8%)76 (64.2%)276 (11.8%)263 (11.3%)13 (6.9%)UICRb0.0010.003 Quartile 1774 (30.4%)760 (30.5%)14 (13.2%)472 (20.1%)447 (20.0%)25 (13.9%) Quartile 2643 (25.2%)617 (25.1%)26 (23.5%)573 (24.5%)542 (25.5%)31 (17.2%) Quartile 3587 (23.1%)556 (23.8%)31 (30.1%)611 (26.1%)566 (25.9%)45 (25.0%) Quartile 4541 (21.3%)501 (20.6%)40 (33.2%)687 (29.3%)608 (28.6%)79 (43.9%)Anti-TPO Ab\<0.001\<0.001 Absence2442 (96.0%)2348 (96.5%)94 (84.7%)2114 (90.2%)1977 (91.8%)137 (73.6%) Presence103 (4.0%)86 (3.5%)17 (15.3%)229 (9.8%)186 (8.2%)43 (26.4%)CKD stage0.4910.694 Stage 1, 22445 (96.0%)2338 (96.1%)107 (97.3%)2262 (96.5%)2090 (95.9%)172 (96.5%) Stage 3, 4, 5100 (4.0%)96 (3.9%)4 (2.7%)81 (3.5%)73 (4.1%)8 (3.5%)[^2]

### Using the population-based TSH reference range (SCH-P)

A total of 4801 subjects were analyzed for the same variables as shown in [Table 1](#tbl1){ref-type="table"}; 2303 (46.1%) were women and most (74.3%) were urban area residents. Details are shown in [Table 2](#tbl2){ref-type="table"}. UICR was uniformly distributed by quartile, and TPOAb was undetectable in 4472 (93.4%) participants. As shown in [Table 2](#tbl2){ref-type="table"}, there was a significant difference between men and women in the frequency of smokers. The baseline values of other variables are similar to those shown in [Table 1](#tbl1){ref-type="table"} and are summarized in [Table 3](#tbl3){ref-type="table"}. [Table 4](#tbl4){ref-type="table"} shows the baseline characteristics analyzed by sex. Table 3Baseline characteristics of subjects when population-based TSH reference range (0.62--6.68 µIU/mL) is used.Total subjects (n = 4801)Subclinical hypothyroidismP valueNo (n = 4644)Yes (n = 157)Age (years)0.011 19--29984 (20.4%)957 (20.6%)27 (17.2%) 30--39882 (18.4%)863 (18.5%)19 (12.2%) 40--49939 (19.6%)904 (19.5%)35 (22.3%) 50--59997 (20.8%)950 (20.5%)47 (29.9%) 60--69908 (18.9%)883 (19.0%)25 (15.9%) 70 and above91 (1.9%)87 (1.9%)4 (2.5%)Sex\<0.001 Male2498 (53.9%)2440 (54.5%)58 (36.4%) Female2303 (46.1%)2204 (45.5%)99 (63.6%)BMI (kg/m2)0.944 \<18.5207 (4.0%)199 (4.0%)8 (4.2%) ≥18.5, \<231859 (38.3%)1795 (38.2%)64 (38.9%) ≥23, \<251141 (24.2%)1103 (24.2%)38 (25.7%) ≥251594 (33.5%)1547 (33.6%)47 (31.2%)Region of residencea0.076 Rural1293 (25.7%)1258 (25.9%)35 (19.1%) Urban3508 (74.3%)3386 (74.1%)122 (80.9%)Family history of thyroid disease0.119 No4565 (95.1%)4411 (95.0%)154 (98.0%) Yes236 (4.9%)233 (5.0%)3 (2.0%)Smoking\<0.001 No2641 (54.5%)2534 (54.0%)107 (70.8%) Yes2160 (45.5%)2110 (46.0%)50 (29.2%)UICRb\<0.001 Quartile 11226 (25.1%)1204 (25.5%)22 (11.8%) Quartile 21196 (25.0%)1167 (25.2%)29 (21.9%) Quartile 31179 (24.9%)1140 (25.0%)39 (24.0%) Quartile 41200 (25.0%)1133 (24.3%)67 (42.3%)Anti-TPO Ab\<0.001 Absence4472 (93.4%)4357 (94.1%)115 (72.2%) Presence329 (6.6%)287 (5.9%)42 (27.8%)CKD stage0.099 Stage 1, 24627 (96.0%)4474 (96.1%)153 (98.3%) Stage 3, 4, 5174 (4.0%)170 (3.9%)4 (1.7%)[^3] Table 4Association with subclinical hypothyroidism according to gender when population-based TSH reference range is used.Male total (n = 2498)Subclinical hypothyroidism (male)P valueFemale total (n = 2303)Subclinical hypothyroidism (female)P valueNo (n = 2440)Yes (n = 58)No (n = 2204)Yes (n = 99)Age (years)0.8520.009 19--29526 (21.1%)513 (21.1%)13 (22.4%)458 (19.9%)444 (20.1%)14 (14.1%) 30--39481 (19.3%)472 (19.4%)9 (15.5%)401 (17.4%)391 (17.7%)10 (10.2%) 40--49492 (19.7%)479 (19.6%)13 (22.4%)447 (19.4%)425 (19.3%)22 (22.3%) 50--59490 (19.6%)477 (19.5%)13 (22.4%)507 (22.0%)473 (21.5%)34 (34.2%) 60--69461 (18.5%)452 (18.5%)9 (15.5%)447 (19.4%)431 (19.6%)16 (16.2%) 70 and above48 (1.8%)47 (1.9%)1 (1.8%)43 (1.9%)40 (1.8%)3 (3.0%)BMI (kg/m2)0.9990.867 \<18.563 (2.5%)62 (2.4%)1 (2.5%)144 (6.3%)137 (6.0%)7 (5.2%) ≥18.5, \<23824 (33.0%)804 (33.5%)20 (33.9%)1035 (44.9%)991 (43.8%)44 (41.7%) ≥23, \<25644 (25.8%)629 (26.0%)15 (25.6%)497 (21.6%)474 (22.0%)23 (25.9%) ≥25967 (38.7%)945 (38.1%)22 (38.0%)627 (27.2%)602 (28.2%)25 (27.2%)Region of residencea0.7100.009 Rural683 (27.3%)666 (25.9%)17 (28.4%)610 (26.5%)592 (26.0%)18 (13.8%) Urban1815 (72.7%)1774 (74.1%)41 (71.6%)1693 (73.5%)1612 (74.0%)81 (86.2%)Family history of thyroid diseaseN/A0.297 No2398 (96.0%)2340 (95.7%)58 (100.0%)2167 (94.1%)2071 (94.1%)96 (96.8%) Yes100 (4.0%)100 (4.3%)0 (0.0%)136 (5.9%)133 (5.9%)3 (3.2%)Smoking0.3750.147 No608 (24.3%)592 (24.9%)16 (30.9%)2033 (88.3%)1942 (88.8%)91 (93.6%) Yes1890 (75.7%)1848 (75.1%)42 (69.1%)270 (11.7%)262 (11.2%)8 (6.4%)UICRb0.0030.033 Quartile 1763 (30.5%)756 (30.4%)7 (11.2%)463 (20.1%)448 (19.8%)15 (12.1%) Quartile 2630 (25.2%)617 (25.0%)13 (21.0%)566 (24.6%)550 (25.4%)16 (22.4%) Quartile 3577 (23.1%)562 (24.0%)15 (28.7%)602 (26.1%)578 (26.1%)24 (21.3%) Quartile 4528 (21.2%)505 (20.6%)23 (39.1%)672 (29.2%)628 (28.7%)44 (44.2%)Anti-TPO Ab\<0.001\<0.001 Absence2396 (96.0%)2349 (96.3%)47 (82.6%)2076 (90.1%)2008 (91.5%)68 (66.2%) Presence102 (4.0%)91 (3.7%)11 (17.4%)227 (9.9%)196 (8.5%)31 (33.8%)CKD stage0.6260.071 Stage 1, 22404 (96.2%)2348 (96.3%)56 (97.4%)2223 (96.5%)2126 (95.8%)97 (98.8%) Stage 3, 4, 594 (3.8%)92 (3.7%)2 (2.6%)80 (3.5%)78 (4.2%)2 (1.2%)[^4][^5]

Prevalence of SCH in the Korean population
------------------------------------------

When SCH-M was used, the prevalence of SCH in Korea was 5.6% (291 subjects) ([Table 1](#tbl1){ref-type="table"}) of whom 180 (60.3%) were women. TPOAb was detected in 60 (22.0%) subjects with SCH. There were 119 subjects in the highest quartile of UICR, accounting for 39.3% of all subjects with SCH. The prevalence of SCH differed significantly based on sex, the presence of TPOAb and UICR quartile (*P* \< 0.001). As shown in [Table 2](#tbl2){ref-type="table"}, the prevalence of SCH was 4.4% (111 of 2545) in men and 7.7% (180 of 2343) in women.

When SCH-P was used, SCH was confirmed in 157 participants with a prevalence of 3.3%. As with SCH-M, the occurrence of SCH significantly differed based on sex, presence of TPOAb and UICR quartile ([Table 3](#tbl3){ref-type="table"}).

In addition, there was a significant difference in the incidence of SCH according to smoking status regardless of the reference range used ([Tables 1](#tbl1){ref-type="table"} and [3](#tbl3){ref-type="table"}). However, when we analyzed male and female subjects separately using SCH-M, this difference was observed only in men ([Table 2](#tbl2){ref-type="table"}). As shown in [Table 4](#tbl4){ref-type="table"}, the prevalence of SCH using SCH-P was found to be 2.3% in men (58 of 2498 men) and 4.3% in women (99 of 2303 women).

Risk factors associated with SCH
--------------------------------

[Tables 5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"} show the ORs for the occurrence of SCH for each variable according to the TSH reference range used and sex. [Table 5](#tbl5){ref-type="table"} shows the relationship between different variables and the occurrence of SCH based on SCH-M. In the adjusted model, smoking significantly reduced the incidence of SCH in men (OR 0.58, CI: 0.34--1.00, *P* = 0.048). We also found that when TPOAb was positive, the occurrence of SCH was significantly increased in both crude (OR 5.03, CI: 2.68--9.45, *P* \< 0.001) and adjusted (OR 5.59, CI: 2.82--11.09, *P* \< 0.001) models. For urine iodine, the risk of SCH increased as the UICR quartile increased in the adjusted model ([Table 5](#tbl5){ref-type="table"}). For women, positivity for TPOAb was confirmed as a risk factor for SCH, as was the highest iodine quartile (OR 2.41, CI: 1.44--4.05, *P* \< 0.001). In addition, the OR for SCH in urban vs rural residence was 1.78 (CI: 1.15--2.75, *P* = 0.010). Similar results (summarized in [Table 6](#tbl6){ref-type="table"}) were obtained using SCH-P. Table 5Logistic regression analysis of subjects with subclinical hypothyroidism (kit manufacturer suggested TSH reference range is used).Crude modelAdjusted modelOdds ratio (95% CI)P valueOdds ratio (95% CI)P valueMale Age (years)  19--29ReferenceReference  30--390.63 (0.32--1.25)0.2900.58 (0.29--1.19)0.136  40--490.70 (0.38--1.31)0.5070.66 (0.33--1.32)0.236  50--590.75 (0.40--1.43)0.7060.62 (0.30--1.28)0.196  60--690.75 (0.38--1.50)0.7200.60 (0.27--1.31)0.199  70 and above1.25 (0.43--3.62)0.3380.97 (0.32--2.93)0.955 BMI (kg/m2)  \<18.5Reference  ≥18.5, \<231.48 (0.20--11.23)0.793  ≥23, \<251.76 (0.12--13.68)0.770  ≥252.55 (0.34--19.08)0.112 Region of residencea  RuralReference  Urban0.72 (0.45--1.14)0.163 Family history of thyroid disease  NoReference  Yes0.99 (0.30--3.22)0.982 Smoking  NoReference  Yes0.57 (0.36--0.92)0.0220.58 (0.34--1.00)0.048 UICRb  Quartile 1ReferenceReference  Quartile 22.17 (1.06--4.43)0.9262.52 (1.27--5.02)0.009  Quartile 32.93 (1.51--5.68)0.1103.57 (1.86--6.84)0.001  Quartile 43.75 (1.92--7.34)0.0024.41 (2.28--8.52)\<0.001 Anti-TPO Ab  AbsenceReferenceReference  Presence5.03 (2.68--9.45)\<0.0015.59 (2.82--11.09)\<0.001 CKD stage  Stage 1, 2Reference  Stage 3, 4, 50.70 (0.26--1.94)0.495Female Age (years)  19--29ReferenceReference  30--390.91 (0.49--1.69)0.1050.74 (0.40--1.36)0.328  40--491.15 (0.64--2.07)0.5180.87 (0.48--1.58)0.646  50--592.05 (1.19--3.53)0.0131.33 (0.76--2.35)0.320  60--691.12 (0.62--2.04)0.4410.74 (0.39--1.42)0.367  70--2.14 (0.81--5.64)0.1941.61 (0.60--4.27)0.341 BMI (kg/m2)  \<18.5Reference  ≥18.5, \<231.09 (0.53--2.26)0.491  ≥23, \<251.54 (0.72--3.29)0.144  ≥251.27 (0.60--2.70)0.757 Region of residencea  RuralReference  Urban1.78 (1.15--2.75)0.010 Family history of thyroid disease  NoReference  Yes0.81 (0.38--1.75)0.597 Smoking  NoReference  Yes0.58 (0.30--1.11)0.0980.64 (0.33--1.23)0.177 UICRb  Quartile 1ReferenceReference  Quartile 21.18 (0.63--2.23)0.3501.17 (0.62--2.21)0.636  Quartile 31.45 (0.83--2.54)0.8731.46 (0.82--2.60)0.203  Quartile 42.34 (1.40--3.90)\<0.0012.41 (1.44--4.05)\<0.001 Anti-TPO Ab  AbsenceReferenceReference  Presence4.00 (2.59--6.16)\<0.0014.06 (2.63--6.28)\<0.001 CKD stage  Stage 1, 2Reference  Stage 3, 4, 50.85 (0.37--1.94)0.695[^6] Table 6Logistic regression analysis of subjects with subclinical hypothyroidism (population-based TSH reference range is used).Crude modelAdjusted modelOdds ratio (95% CI)P valueOdds ratio (95% CI)P valueMale Age (years)  19--29ReferenceReference  30--390.64 (0.25--1.66)0.6560.56 (0.20--1.53)0.254  40--490.87 (0.37--2.08)0.6650.76 (0.29--2.00)0.581  50--591.10 (0.48--2.56)0.2390.81 (0.31--2.15)0.674  60--690.78 (0.28--2.20)0.9400.54 (0.16--1.89)0.336  70 and above0.39 (0.05--3.09)0.4340.27 (0.03--2.07)0.205 BMI (kg/m2)  \<18.5Reference  ≥18.5, \<230.99 (0.13--7.59)0.986  ≥23, \<250.97 (0.12--7.71)0.959  ≥250.98 (0.13--7.55)0.986 Region of residencea  RuralReference  Urban0.88 (0.46--1.71)0.710 Family history of thyroid disease  No  YesN/AN/A Smoking  NoReference  Yes0.74 (0.38--1.45)0.3770.73 (0.34--1.58)0.423 UICRb  Quartile 1ReferenceReference  Quartile 22.27 (0.84--6.16)0.7492.57 (0.92--7.13)0.071  Quartile 33.24 (1.21--8.63)0.3123.75 (1.34--10.51)0.012  Quartile 45.14 (2.06--12.83)0.0025.80 (2.22--15.15)\<0.001 Anti-TPO Ab  AbsenceReferenceReference  Presence5.47 (2.42--12.33)\<0.0015.65 (2.33--13.71)\<0.001 CKD stage  Stage1, 2Reference  Stage 3, 4, 50.70 (0.17--2.96)0.629Female Age (years)  19--29ReferenceReference  30--390.86 (0.374--2.01)0.1620.67 (0.28--1.63)0.379  40--491.60 (0.75--3.44)0.4871.17 (0.53--2.59)0.694  50--592.74 (1.28--5.88)0.0021.68 (0.76--3.74)0.202  60--691.19 (0.49--2.85)0.6680.73 (0.28--1.89)0.519  70--1.31 (0.33--5.20)0.9630.97 (0.25--3.69)0.960 BMI (kg/m2)  \<18.5Reference  ≥18.5, \<231.10 (0.43--2.84)0.871  ≥23, \<251.36 (0.50--3.71)0.419  ≥251.11 (0.41--2.99)0.920 Region of residencea  RuralReference  Urban2.18 (1.19--3.99)0.011 Family history of thyroid disease  NoReference  Yes0.52 (0.15--1.82)0.306 Smoking  NoReference  Yes0.54 (0.23--1.26)0.1550.60 (0.25--1.40)0.237 UICRb  Quartile 1ReferenceReference  Quartile 21.45 (0.63--3.37)0.9211.40 (0.59--3.29)0.445  Quartile 31.34 (0.64--2.80)0.6211.31 (0.61--2.81)0.493  Quartile 42.52 (1.30--4.88)\<0.0012.67 (1.35--5.26)0.005 Anti-TPO Ab  AbsenceReferenceReference  Presence5.49 (3.26--9.22)\<0.0015.33 (3.19--8.90)\<0.001 CKD stage  Stage 1, 2Reference  Stage 3, 4, 50.28 (0.06--1.24)0.093[^7][^8]

Discussion
==========

This study separately evaluated factors related to high prevalence of SCH in men and women to identify sex-specific risk factors for SCH. In both sexes, regardless of whether SCH-P or SCH-M was applied, TPOAb positivity and high-iodine intake were related to the development of SCH. However, it was observed that the effect of iodine excess was more marked in men than in women. Urban residence was associated with SCH only in women.

Using SCH-M, the overall prevalence of SCH in Korea was 6.0% (4.4% in men, 7.7% in women). Using SCH-P, the overall prevalence of SCH was 3.3% (2.3% in men, 4.3% in women). The prevalence of SCH in Korea was reported previously to be 0.1--5.4% based on data from health care examinations ([@bib15], [@bib22], [@bib23], [@bib24], [@bib25]). However, these studies had limitations: their data were not representative of the whole population because the TSH cut-off levels used were different, and the results included only those subjects who underwent health care examinations. However, it is noteworthy that a similar prevalence was confirmed in our study using both a population-based TSH cut-off (SCH-P) and that suggested by the manufacturer of a commonly used kit (SCH-M).

Although the prevalence of SCH varies with geographical region, race, age, sex and TSH measurement method, most studies report that age, presence of autoantibody, female sex and iodine intake are risk factors for SCH ([@bib2]). Most epidemiological studies have shown a higher prevalence of SCH in women than in men, but the underlying cause of this female predominance is unclear ([@bib2]). The higher prevalence of autoantibodies is one possible cause. Pedersen *et al*. analyzed 4649 Danish subjects and reported that autoantibodies were more frequent in women ([@bib26]). The prevalence of SCH was also associated with the presence of TPOAb. In the USA, National Health and Nutrition Examination Survey (NHANES) III reported a trend to higher prevalence of SCH in subjects who were positive for TPOAb ([@bib4]). The Whickham survey reported similar results to those of NHANES III and showed that the ORs of developing overt hypothyroidism were four times higher in subjects with positive autoantibodies ([@bib27]). Iodine intake is another risk factor for SCH. Excessive iodine intake is known to cause thyroid dysfunction through direct toxic effects or immunological alterations ([@bib28]). The prevalence of SCH has been shown to differ depending on whether it is reported from iodine-sufficient areas or from areas with an iodine deficit. According to the Laurberg study conducted in Northern Europe in 1998, the prevalence of SCH in Iceland, which is an iodine-sufficient area, was 18%, while that in the iodine-deficient area of Jutland, Denmark was 3.8% ([@bib7]). A study in China by Teng *et al*. reported that the prevalence of SCH differed between three regions according to their iodine intake, and a significant association between SCH and iodine intake was confirmed ([@bib29]).

In our study, previously known risk factors for SCH were identified in both sexes regardless of the reference range used. The presence of TPOAb and the highest quartile of UICR increased ORs significantly in both men and women. Interestingly, we found that the change in risk of SCH according to the magnitude of iodine excess differed between sexes. Based on our results, men are more vulnerable to excessive iodine intake in terms of development of SCH; a modest increase in iodine intake leads to a rapid increase in SCH risk. This finding was consistent regardless of the TSH cut-off used. Using SCH-M, the ORs for SCH increased 2.5 times in the second quartile, 3.6 times in the third quartile and 4.4 times in the highest quartile relative to the lowest quartile (adjusted model shown in [Table 5](#tbl5){ref-type="table"}). When SCH-P was used, the ORs for SCH increased 2.6 times in the second quartile, 3.8 times in the third quartile and 5.8 times in the highest quartile (adjusted model shown in [Table 6](#tbl6){ref-type="table"}). In contrast, no sharp increase in ORs was observed in women as their UICR quartile increased. Even for those women in the highest quartile for UICR, the ORs did not exceed 3 (2.4 with SCH-M and 2.7 with SCH-P ([Tables 5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"}, respectively).

Although the reason for this difference is not clear, there are several possible explanations. First, although the thyroid is the main reservoir for iodine intake, breast and cervical tissues are known to be involved in extrathyroidal iodine storage ([@bib30]); thus, women are more capable of providing storage for excess iodine. Therefore, it may be that accumulation of excess iodine in the extrathyroidal tissues, which would attenuate iodine accumulation in the thyroid, may mitigate the adverse effects of excessive iodine intake on the development of SCH. Second, estrogen has been demonstrated to have effects on thyroidal iodine uptake and TPO activity in animal models ([@bib31]). Previous studies suggested that oestradiol might regulate iodide uptake via its action on the sodium/iodide symporter (NIS) and TPO, proteins that play important roles in thyroid hormone biosynthesis ([@bib32], [@bib33], [@bib34]). Oestradiol directly stimulates iodine uptake while regulating iodine uptake via reducing NIS or TPO gene expression ([@bib33]). It is thought that oestradiol may regulate the effect of iodine on thyroid function. Because of the role of estrogen, the degree of response to iodine intake may differ in men and women. In other words, estrogen may modulate the effect of excessive iodine on thyroid tissue in women, which may reduce the risk of SCH. However, considering that thyroid dysfunction frequently occurs in women, additional research is needed to evaluate other factors such as the concentrations of oestradiol and other co-factors.

Another distinctive finding of our study is the increased risk associated with the area of residence. In women, the risk of SCH was significantly higher in urban area residents than in rural area residents regardless of the TSH cut-off level used. The risk of SCH in urban residents was 1.78 times higher using SCH-M and 2.18 times higher using SCH-P ([Tables 5](#tbl5){ref-type="table"} and [6](#tbl6){ref-type="table"}, respectively). Although the underlying mechanism of this difference is unclear, it is possible that urban women have more opportunities to consume high-iodine meals or supplementation. However, a detailed survey to elucidate the lifestyle or food-intake patterns in terms of iodine exposure would be required to establish this.

Our study has several limitations. First, it is a cross-sectional study and hence does not prove causality. Second, the presence of thyroid disease, dementia or other medical illness was self-reported. The use of medication and the detailed history of treatment were also assessed based on the information participants provided.

In conclusion, we examined the prevalence of SCH and the associated risk factors in the Korean population using the most recently released nationally representative data. The TSH reference ranges were calculated using two methods (the values proposed by the test kit manufacturer and population-based values) and the risk factors associated with SCH were analyzed. The prevalence rates of SCH were similar to those reported in the literature and previously known risk factors were confirmed using both TSH reference ranges. The notable findings of this study are that the increase in the risk of SCH with increasing iodine intake is more marked in men than in women and that residential area could be a risk factor for SCH in women. Further studies are needed to identify the mechanisms involved in these effects.
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[^1]: \*Data are presented as mean ± [s.d.]{.smallcaps}, *n* (weighted %), statistics were carried out using Rao-Scott Chi-square test; ^a^classification of the area of residence is classified according to the administrative division of Korea; ^b^iodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: \<Q1 (141.53203438), quartile 2: ≥Q1 and \<Q2 (281.81447737), quartile 3: ≥Q2 and \<Q3 (664.64655625), quartile 4: ≥Q3.

[^2]: \*Data are presented as mean ± [s.d.]{.smallcaps}, *n* (weighted %), statistics were carried out using Rao-Scott chi-square test; ^a^classification of the area of residence is classified according to the administrative division of Korea; ^b^iodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: \<Q1 (141.53203438), quartile 2: ≥Q1 and \<Q2 (281.81447737), quartile 3: ≥Q2 and \<Q3 (664.64655625), quartile 4: ≥Q3.

[^3]: \*Data are presented as mean ± [s.d.]{.smallcaps}, *n* (weighted %), statistics were carried out using Rao-Scott Chi-square test; ^a^classification of the area of residence is classified according to the administrative division of Korea; ^b^iodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: \<Q1 (141.53203438), quartile 2: ≥Q1 and \<Q2 (281.81447737), quartile 3: ≥Q2 and \<Q3 (664.64655625), quartile 4: ≥Q3.

[^4]: \*Data are presented as mean ± [s.d.]{.smallcaps}, *n* (weighted %), statistics were carried out using Rao-Scott Chi-square test; ^a^classification of the area of residence is classified according to the administrative division of Korea; ^b^iodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: \<Q1 (141.53203438), quartile 2: ≥Q1 and \<Q2 (281.81447737), quartile 3: ≥Q2 and \<Q3 (664.64655625), quartile 4: ≥Q3.

[^5]: N/A, not available.

[^6]: \*Data are presented OR (95% CI), statistics were carried out using logistic regression; ^a^classification of the area of residence is classified according to the administrative division of Korea; ^b^iodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: \<Q1 (141.53203438), quartile 2: ≥Q1 and \<Q2 (281.81447737), quartile 3: ≥Q2 and \<Q3 (664.64655625), quartile 4: ≥Q3.

[^7]: \*Data are presented OR (95% CI), statistics were carried out using logistic regression; ^a^classification of the area of residence is classified according to the administrative division of Korea; ^b^iodine intake status was evaluated by urine iodine creatinine ratio, quartile 1: \<Q1 (141.53203438), quartile 2: ≥Q1 and \<Q2 (281.81447737), quartile 3: ≥Q2 and \<Q3 (664.64655625), quartile 4: ≥Q3.
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